InsidersTradesSigma
Track the ELI LILLY AND COMPANY share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €1,056.9bn. The latest transaction was reported on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: LILLY ENDOWMENT, INC.. Every trade is free.
3
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ELI LILLY AND COMPANY Buy (bullish), based on 26 analysts. Average price target: US$1,297.31.
13Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,298 of 28,835 companies
58.6
score / 100
Value31
Quality86
FCF yld0.5%
Earn yld1.9%
EV/EBITDA36.4x
ROE102%
Gross mgn83%
Net mgn32%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 August 2026
Declarations3 total
2,000 shares@ US$1,185.71CommonSEC144:0001950047-26-007881
310,000 shares@ US$1,200.06100.0% of flowCommon StockSEC144:0000316011-26-000025
305,000 shares@ US$1,127.6948.2% of flowCommon StockSEC144:0000316011-26-000023
3 of 3 declarations
About ELI LILLY AND COMPANY
ELI LILLY AND COMPANY is an American pharmaceutical company engaged in the research, development, and marketing of medications. It focuses on areas such as diabetes, oncology, and immunological diseases.